Price
128.4
+0.54%52W Range
Market Cap
₹1,142.08 Cr
Traded: ₹0.59 Cr (0.05%) 0.0x
Free Float: ₹322.98 Cr (0.18% of FF traded)
Volume · 60D trend
45.93 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | -- | -- | -- | +4.0% | -- | -- |
| ROE | -- | -- | +8.0% | -- | -- | -- |
| Sales | -- | -- | -- | -- | +8.0% | -- |
| Profit | -- | -- | -- | -- | +50.0% | -- |
Quarterly Results
Dec 2023
Sep 2023
Jun 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 107 | 143 | 121 | 107 | 96 | 129 | 101 | 103 | 104 | 116 | 100 | 92 | 88 |
| Expenses | 98 | 111 | 104 | 99 | 91 | 113 | 91 | 87 | 94 | 97 | 88 | 83 | 82 |
| Operating Profit | 8 | 32 | 17 | 8 | 5 | 17 | 10 | 16 | 10 | 18 | 12 | 9 | 6 |
| OPM % | 7.9% | 22.4% | 14.2% | 7.5% | 5.1% | 12.8% | 9.9% | 15.4% | 9.4% | 15.8% | 12.2% | 10.3% | 6.5% |
| Other Income | 3 | 2 | 1 | 2 | -4 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 4 | 4 |
| Profit Before Tax | 6 | 29 | 13 | 5 | -4 | 14 | 7 | 12 | 7 | 15 | 8 | 6 | 2 |
| Tax % | 27.1% | 6.5% | 31.3% | 44.4% | 3.2% | 38.5% | 38.3% | 29.1% | 28.5% | 35.3% | 30.5% | 20.2% | -35.5% |
| Net Profit | 4 | 27 | 9 | 3 | -4 | 9 | 4 | 9 | 5 | 9 | 6 | 5 | 3 |
| Exceptional Items | -- | 0 | -2 | 0 | -7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 0.5 | 3.1 | 1.0 | 0.3 | -0.5 | 1.0 | 0.5 | 1.0 | 0.6 | 1.1 | 0.7 | -- | -- |
| Sales Growth (YoY) | -- | 10.6% | 19.6% | 3.8% | -7.9% | 11.9% | 1.8% | 12.0% | 19.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 18.2% | 13.1% | 11.5% | -25.6% | 27.7% | -1.9% | -1.0% | -10.3% | 16.0% | 8.7% | 4.5% | -- |
| OP Growth (YoY) | 73.9% | 93.8% | 71.7% | -49.2% | -50.6% | -9.3% | -17.6% | 67.1% | 71.9% | -- | -- | -- | -- |
| OP Growth (QoQ) | -73.7% | 86.8% | 114.1% | 65.2% | -70.7% | 65.5% | -36.7% | 60.9% | -46.2% | 50.4% | 28.3% | 65.6% | -- |
| Profit Growth (YoY) | -- | 214.0% | 132.0% | -67.0% | -55.0% | -7.0% | -25.0% | 71.0% | 49.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 215.5% | 104.2% | -67.7% | -182.5% | -7.6% | -26.1% | -- | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 212.2% | 206.3% | 168.1% | -148.4% | 102.1% | -51.5% | 73.7% | -45.7% | 61.5% | -- | -- | -- |
| OP Margin | -- | 22.4% | 14.1% | 7.5% | 5.2% | 13.2% | 9.9% | 15.5% | 9.6% | 15.5% | 12.0% | 9.8% | 6.8% |
| Net Margin | -- | 18.9% | 7.4% | 2.8% | -4.2% | 7.0% | 4.0% | 8.7% | 4.8% | 7.8% | 6.0% | 5.4% | 3.4% |
| Material Cost % | -- | 34.9% | 35.9% | 36.2% | 36.0% | 40.2% | 37.1% | 33.5% | 35.8% | 36.8% | 37.3% | 34.4% | 38.1% |
| Employee Cost % | -- | 12.5% | 17.8% | 19.3% | 20.9% | 15.3% | 19.2% | 18.0% | 18.4% | 15.8% | 18.9% | 22.0% | 20.4% |
| P/S | 2.39 | 2.92 | 2.34 | 2.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 26.47 | 39.44 | 66.32 | 79.78 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.59 | 3.09 | 2.62 | 2.28 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of allotment of 4,475 equity shares against stock options exercised under the Company''s ESOP Scheme
Outcome of Board Meeting
Borosil Scientific Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Change in Senior Managerial Personnel of the Company
Please find enclosed the Compliance Certificate under Reg.74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026
As per the attachment
The Exchange has sought clarification from Borosil Scientific Ltd on June 30, 2026, with reference to Movement in Volume.<BR><BR>The reply is awaited.
Intimation for closure of Trading Window for the quarter ending June 30, 2026.
Investor Presentation on financial results for the quarter and financial year ended March 31, 2026
Annual Secretarial Compliance Report for the Financial Year 2025-26
Grant of Stock Options under Borosil Scientific Limited- Employee Stock Option Scheme
Outcome of Board Meeting.
Appointment of Company Secretary & Compliance Officer
Resignation of Company Secretary & Compliance Officer.
Re-appointment of Mr. Vinayak Madhukar Patankar as Whole-Time Director.
Outcome for Board Meeting held on May 20, 2026 For The Quarter And Financial Year Ended March 31, 2026
Borosil Scientific Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2026 ,inter alia, to consider and approve Audited Financial Results ....
Certificate under Regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018 for the Quarter ended March 31, 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shreevar Kheruka
Closure of Trading Window
Investor presentation for unaudited financial results for quarter and nine months ended December 31, 2025
Grant of Stock Options under Borosil Scientific Limited - Employee Stock Option Scheme
Financial Results for the quarter and nine months ended December 31, 2025
Financial Results for the quarter and nine months ended December 31, 2025
Borosil Scientific Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve Borosil Scientific Ltd has ....
Certificate for the quarter ended December 31, 2025
Closure of Trading Window
Update on Credit Rating is Enclosed
Further investment in Goel Scientific Glass works Limited, subsidiary of the Company, through rights issue
Investor Presentation for Unaudited Financial Results for the quarter and half year ended September 30, 2025
Financial Results for the quarter and half year ended September 30, 2025
Financial Results for the quarter and half year ended September 30, 2025
Borosil Scientific Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve Meeting of the Board of ....
Certificate under Regulation 74(5) of the SEBI (Depository and Participants) Regulations, 2018 for the quarter ended September 30, 2025
Company''s Response Attached
Intimation of Closure of Trading Window
Appointment of Mr. Kailash Motwani as Head Operations, Pune & GSGWL (Senior Management Personnel)
Mr. Prashant Gangadhar Amin, Business Head - Pharmaceutical Primary Packaging (Senior Management Personnel) has tendered his resignation from the service of the Company with effect from ....
Appointment of Mr. Paresh Thaker as an Associate Vice President & Plant Head, Nashik.
Investor presentation w.r.t. the unaudited financial results for the quarter ended June 30, 2025 is attached.
Intimation under Regulation 44 of SEBI Listing Regulations is enclosed
The voting results and scrutinizer''s report for the 34th AGM is attached.
The proceedings of the 34 AGM is attached.
Results attached
Board Meeting Outcome for the quarter ended June 30, 2025 is attached
Borosil Scientific Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2025 ,inter alia, to consider and approve Board Meeting Intimation ....
Intimation of allotment of 1,122 equity shares against stock options exercised under the Company''s ESOP Scheme
Newspaper Publication - Dispatch of annual report
Intimation for letter to the members providing web-link for Annual Report for the financial year 2024-25
Annual Report including Notice of 34th AGM scheduled to be held on August 11, 2025 is attached